Piper Sandler Companies

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

Retrieved on: 
Tuesday, April 9, 2024
Therapy, SAN, Liver, Piper Sandler Companies

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024.
  • Please contact your Piper Sandler representative to schedule a one-on-one meeting.

Praxis Precision Medicines to Participate in Upcoming April Conferences

Retrieved on: 
Friday, April 5, 2024
Praxis, Central nervous system, Webcast, CNS, Conference, Piper Sandler Companies

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.

Key Points: 
  • BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.
  • Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place virtually on April 8, 2024 at 8:00a.m EDT.
  • A replay of the webcast will be available on Praxis’ website for 90 days following the event.
  • Management will also participate in the Piper Sandler Spring Biopharma Symposium, taking place in Boston, MA on April 16-17, 2024.

ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium

Retrieved on: 
Wednesday, April 3, 2024
Encore Boston Harbor, ANI, Piper Sandler Companies

BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.

Key Points: 
  • BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.
  • To schedule a 1x1 meeting with the Company, please email [email protected] .

Inari Medical, Inc. (NARI) Plummets on News of DOJ Investigation – Hagens Berman

Retrieved on: 
Monday, April 1, 2024
NARI, Medicine, Health, Piper Sandler Companies, News, Person, Disclosure, DOJ, Justice, Hagens Berman, Pharmaceutical industry

Inari Medical shares recently tumbled after the commercial-stage medical device company disclosed it was being investigated by the DOJ over certain payments to healthcare professionals.

Key Points: 
  • Inari Medical shares recently tumbled after the commercial-stage medical device company disclosed it was being investigated by the DOJ over certain payments to healthcare professionals.
  • But on Feb. 29, 2024, the true drivers of Inari’s revenue growth came into question, when Inari revealed that federal regulators had initiated an investigation into its payments to Health Care Professionals (“HCPs”) sometime during Dec. 2023.
  • This news sent the price of Inari shares crashing $12.14, or down about 21%, on Feb. 29, 2024.
  • “We are investigating the propriety of Inari’s touted revenue growth and repeated claims that its strategy had positioned it for sustained operating profitability by the first half of 2025,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Retrieved on: 
Monday, April 1, 2024
Immune system, Conference, Piper Sandler Companies

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.

Key Points: 
  • BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Inari Medical, Inc. (NARI) Investors with Substantial Losses to Contact Firm, NARI Plummets on News of DOJ Investigation – Hagens Berman

Retrieved on: 
Thursday, March 28, 2024
NARI, Health, Piper Sandler Companies, SAN, News, Person, Disclosure, DOJ, Justice, Hagens Berman, Pharmaceutical industry

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses now .
  • Inari Medical shares recently tumbled after the commercial-stage medical device company disclosed it was being investigated by the DOJ over certain payments to healthcare professionals.
  • This news sent the price of Inari shares crashing $12.14, or down about 21%, on Feb. 29, 2024.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

Piper Sandler Completes 47th Semi-Annual Taking Stock With Teens® Survey

Retrieved on: 
Tuesday, April 9, 2024
Technology, Communications, Entertainment, Food, Beverage, Research, Fashion, Teens, Generation Z, Cosmetics, Retail, Restaurant, Bar, Finance, Banking, Social Media, Professional Services, Data Analytics, Science, Other Technology, Consumer, Other Entertainment, Online Retail, Online, Other Retail, Tea, Celsius, Growth, Netflix, Piper Sandler Companies, Chick-fil-A, Partnership, Nike, Beauty, Coffee, Social media, Running, DECA, Red Bull, Starbucks, Multimedia, Gen

Piper Sandler Companies (NYSE: PIPR), a leading investment bank, completes its 47th semi-annual Taking Stock With Teens® survey in partnership with DECA.

Key Points: 
  • Piper Sandler Companies (NYSE: PIPR), a leading investment bank, completes its 47th semi-annual Taking Stock With Teens® survey in partnership with DECA.
  • The Piper Sandler equity research team now has more than 61 million data points around teen preferences and spending in the 23 plus years of researching teens.
  • To see the full list of key findings, view the report summary and request the full survey report, visit pipersandler.com/teens .
  • We are seeing some significant shifts in brand preferences including the rise of smaller, innovative brands which are taking share from incumbents.

Inari Medical, Inc. (NARI) Plummets on News of DOJ Investigation – Hagens Berman

Retrieved on: 
Monday, March 25, 2024
NARI, Health, Piper Sandler Companies, SAN, News, Person, Disclosure, DOJ, Justice, Hagens Berman

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses now .
  • Inari Medical shares recently tumbled after the commercial-stage medical device company disclosed it was being investigated by the DOJ over certain payments to healthcare professionals.
  • But on Feb. 29, 2024, the true drivers of Inari’s revenue growth came into question, when Inari revealed that federal regulators had initiated an investigation into its payments to Health Care Professionals (“HCPs”) sometime during Dec. 2023.
  • This news sent the price of Inari shares crashing $12.14, or down about 21%, on Feb. 29, 2024.

Inari Medical, Inc. (NARI) Plummets on News of DOJ Investigation – Hagens Berman

Retrieved on: 
Thursday, March 21, 2024
NARI, Medicine, Health, Piper Sandler Companies, News, Person, Disclosure, DOJ, Justice, Hagens Berman, Pharmaceutical industry

Inari Medical shares recently tumbled after the commercial-stage medical device company disclosed it was being investigated by the DOJ over certain payments to healthcare professionals.

Key Points: 
  • Inari Medical shares recently tumbled after the commercial-stage medical device company disclosed it was being investigated by the DOJ over certain payments to healthcare professionals.
  • But on Feb. 29, 2024, the true drivers of Inari’s revenue growth came into question, when Inari revealed that federal regulators had initiated an investigation into its payments to Health Care Professionals (“HCPs”) sometime during Dec. 2023.
  • This news sent the price of Inari shares crashing $12.14, or down about 21%, on Feb. 29, 2024.
  • “We are investigating the propriety of Inari’s touted revenue growth and repeated claims that its strategy had positioned it for sustained operating profitability by the first half of 2025,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Inari Medical, Inc. (NARI) Plummets on News of DOJ Investigation – Hagens Berman

Retrieved on: 
Monday, March 18, 2024
NARI, Health, Piper Sandler Companies, SAN, News, Person, Disclosure, DOJ, Justice, Hagens Berman

SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses now .
  • Inari Medical shares recently tumbled after the commercial-stage medical device company disclosed it was being investigated by the DOJ over certain payments to healthcare professionals.
  • But on Feb. 29, 2024, the true drivers of Inari’s revenue growth came into question, when Inari revealed that federal regulators had initiated an investigation into its payments to Health Care Professionals (“HCPs”) sometime during Dec. 2023.
  • This news sent the price of Inari shares crashing $12.14, or down about 21%, on Feb. 29, 2024.